[
    [
        {
            "time": "2018-01-02",
            "original_text": "Unloved High-Yielders That Will Rise With Rates (and Pay Up to 7% in Cash!)",
            "features": {
                "keywords": [
                    "High-Yielders",
                    "Rise",
                    "Rates",
                    "Cash"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Unloved High-Yielders That Will Rise With Rates (and Pay Up to 7% in Cash!)",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "How Jazz Pharmaceuticals’ Products Performed in the Second Quarter",
            "features": {
                "keywords": [
                    "Jazz Pharmaceuticals",
                    "Products",
                    "Second Quarter",
                    "Performance"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-09",
            "original_text": "New Novan incentive plan targets share price goals and $25M, $50M bonus pools",
            "features": {
                "keywords": [
                    "Novan",
                    "incentive plan",
                    "share price",
                    "bonus pools"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-08-02",
            "original_text": "These Products Contributed to Pfizer’s Growth in Q2 2018",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Products",
                    "Growth",
                    "Q2 2018"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-09",
            "original_text": "Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract",
            "features": {
                "keywords": [
                    "Novan",
                    "Business Update",
                    "10-Q",
                    "Incentive Plan",
                    "CEO Contract"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "The Swiss Stock Market Pulled Back On Roche Weakness",
            "features": {
                "keywords": [
                    "Swiss Stock Market",
                    "Pulled Back",
                    "Roche",
                    "Weakness"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        }
    ]
]